Our Therapies

OCREVUS® Infusion Therapy

image

About OCREVUS Infusion Therapy

It targets a type of immune cell called a CD20-positive B cell that plays a key role in the disease. OCREVUS is approved by the FDA to treat relapsing or primary progressive forms of multiple sclerosis (MS)

image

Condition treated by this therapy

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Primary progressive MS, in adults.

image

OCREVUS Price

The cost of prescription medications can vary depending on your insurance coverage. If you're concerned about the price of your medication:

  • Contact your insurance provider to understand your coverage
  • Ask your doctor or pharmacist about lower-cost alternatives
  • Check with the drug manufacturer about financial assistance programs
  • Explore patient assistance options if you're uninsured or underinsured

Remember, many resources exist to help patients access necessary medications. Don't hesitate to ask for help if you're struggling with medication costs. No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our Violet Health team.

What to Expect During OCREVUS Infusion Therapy

You will receive 2 doses in 3 infusions administered by a trained professional. Your first dose will be split into 2 infusions, 2 weeks apart. Each infusion will last about 2 hours and 30 minutes. ‡ Your second dose (third infusion) will be 6 months later and will last between 2 to 4 hours.

OCREVUS Side Effects

Mild side effects reported in people taking Ocrevus for a relapsing form* of multiple sclerosis (MS) or for clinically isolated syndrome (CIS) include:

  • herpes infections, such as oral herpes (cold sores) or shingles
  • depression
  • upper or lower respiratory infections,† such as the common cold or pneumonia
  • pain in your arms, back, or legs†

Mild side effects in people taking Ocrevus for primary progressive MS (PPMS) include:

  • herpes infections, such as oral herpes or shingles
  • cough
  • diarrhea
  • swelling in your arms or legs
  • upper or lower respiratory infections,† such as the common cold or pneumonia
  • skin infections†

OCREVUS Infusion Therapy at Violet Health

Your comfort during OCREVUS infusion therapy at Violet Health is our priority. Our patients enjoy walk-up parking, complimentary entertainment and snacks, and a team of highly trained providers during each treatment. Plus, Violet Health’s evening and weekend hours and convenient city and rural locations make it easier to schedule your appointments.

imagecursor-move

Violet Health Infusion Centers provides infusion therapy for patients with rare, chronic, or complex conditions in a comfortable, patient-centered atmosphere.

Find Infusion Center Near You!

Helpful Resources

icon

Helpful Resources

Learn More
icon

What is OCREVUS?

Learn More
icon

Treatment Tips

Learn More

Patient Forms

Before you attend your first appointment at Violet Health, please make sure to review the documents below. Please contact us if you have any questions!

image
1

Patient Consent Form

2

HIPAA Privacy Authorization Form

3

Notice of Privacy Practices

4

Patient Rights and Responsibilities

5

Appointment Lateness and Cancelation

Meet our Infusion Specialists

  • Natali Craig

    Natali Craig

    Product Designer

  • Phoenix Baker

    Phoenix Baker

    Engineering Manager

  • Candice Wu

    Candice Wu

    Backend Developer

  • Lana Steiner

    Lana Steiner

    Product Manager

For Provider

Simplify patient referrals and offer advanced treatment options with our infusion partnership program.

For Patient

There may be a better way to manage your condition – explore infusion therapy.

logo

Cutting-edge infusion therapies and injections for patients with complex chronic conditions and rare diseases.

instagramfacebooklinkedinTwitter

© 2024 violet health®: Infusion Care. All rights reserved.